D1.485 - Characterization of CRSwNP and associated Type 2 or Respiratory comorbidities in the biological era in Spain - The POLARIS study

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-standing inflammatory disease that affects the nasal and paranasal sinus mucosa. Along with very disabling sinonasal symptoms such as nasal congestion, loss of smell, runny nose and/or facial pain, coexisting diseases that increase CRSwNP burden are common. 

POLARIS is an observational, retrospective, cross-sectional study using electronic health records from the Telotron® database¹. It includes patients with confirmed CRSwNP diagnosis (ICD-9: 471, ICD-10: J33) prior to or on 31^st July 2025 (index date) and with at least 6 months of records available in the database prior to the index date.

The aim of this communication is to describe prevalence; respiratory and general comorbidities associated with CRSwNP found in the POLARIS study on 31^st July 2025. 

Among the study cohort (893.392 patients ≥18 years old), 0,71% had a diagnosis of CRSwNP. Of these patients, 5,866 patients met inclusion criteria.

Studied population mean (SD) age at index date was 56.7 (16.2) years and 58.8% were male; mean (SD) age at CRSwNP diagnosis was 49.4 (15.7) years and the median (Q1-Q3) disease duration was 7.3 (3.4; 11.3) years.

93.6% of the patients presented at least one of the general and/or respiratory comorbidities listed in Table 1 and 64.3% presented at least one to the T2 inflammatory diseases. The most common T2 inflammatory diseases included allergic rhinitis (39.0%), asthma (30.2%), NSAID-ERD (11.5%), urticaria (11.1%) and atopic dermatitis (9.2%).

Other common respiratory comorbidities were non-allergic rhinitis (31.9%), obstructive sleep apnoea (10.6%) and bronchiectasis (10.3%). The most common general comorbidities were dyslipidaemia (46.0%), anxiety (41.7%), hypertension (37.7%), obesity (21.2%), and chronic cardiac disease (16.8%).

The high burden of comorbidities—especially type 2 inflammatory diseases such as allergic rhinitis and asthma—together with other respiratory and common general comorbidities underscores substantial clinical impact in CRSwNP patients. These findings support multidisciplinary, longitudinal care models and personalized therapeutic strategies aimed at sustained inflammatory control, and comprehensive management of comorbidities.